Step-in rights are contractual provisions allowing one party to assume operational control when the counterparty fails to perform. In pharmaceutical

How the analytical tools of pharmaceutical royalty finance — risk-adjusted NPV, probability weighting, decay curves, and defensibility analysis — translate directly to pricing healthcare data assets. And why the market may be mispricing them right now.

A court ruling in New York has settled a question that most executives never thought to ask. The answer should worry anyone who has ever pasted something sensitive into Claude or ChatGPT.

Biotech and Healthcare Transactions: Week of February 8–14, 2026 The week of February 8–14, 2026 recorded over $25

When Innoviva moved to acquire La Jolla Pharmaceutical in 2022, the transaction revealed a hidden tripwire that many biotech M&

Overview of Epidarex Capital and Strategy Epidarex Capital is a transatlantic venture capital firm focused on early-stage life science and

Company Overview and Technology SpyGlass Pharma (sometimes referred to as SpyGlass Bio) is a late-stage ophthalmic biotechnology company focused on

Vaccine royalties have matured into a distinct sub-asset class, driven by blockbuster revenues from HPV, pneumococcal, shingles, and mRNA vaccines.

OpenAI has publicly floated a revenue model in which it would subsidize AI compute for drug discovery firms in exchange

Every royalty transaction carries a map. Before the discount rate is set, before the cap structure is negotiated, before the first dollar changes hands, the most consequential question in pharmaceutical royalty financing is deceptively simple: where does the money come from?